An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

计划入组 75 人 · 首次发布于 2024 年 5 月 30 日

Study of STG-001 in Subjects With Stargardt Disease

计划入组 10 人 · 首次发布于 2020 年 7 月 28 日

Safety and Efficacy of a Single Subretinal Injection of JWK006 Gene Therapy in Subjects With Stargardt Disease(STGD1)

计划入组 9 人 · 首次发布于 2024 年 3 月 8 日

ABCA4 DNA nanoparticles (Copernicus Therapeutics)

AAVB-039

Stargardt disease-gene therapy (IVERIC bio)

NHI-1

United States

Xi'an No.1 Hospital

China

ALPHA-1 FOUNDATION, INC.

United States

Belite Bio Raises $350 Million to Advance Retinal Disease Therapies Toward Commercialization

Belite Bio's Tinlarebant Achieves 35.7% Reduction in Lesion Growth in First Successful Phase 3 Trial for Stargardt Disease

Belite Bio's Tinlarebant Shows Progress in Stargardt Disease and Geographic Atrophy Trials